On May 19, 2026, Corcept Therapeutics Incorporated (the "Company") learned that the United States Department of Justice (the "DOJ") had filed a Notice of Election to Decline Intervention (the "Notice") in a civil qui tam action filed against the company, captioned U.S. et al. ex rel. Stephen Elliott v. Corcept Therapeutics, Inc., No. 17-CV-1303 (SRC) (D.N.J.). That action was initiated in February 2017, in the District Court of New Jersey, by a former employee of the Company (the "Relator"). In connection with that action, the DOJ previously issued a records subpoena to the Company in November 2021, seeking information relating to the sale and promotion of Korlym®, the Company's relationships with and payments to health care professionals who prescribe or recommend Korlym, and prior authorizations and reimbursement for Korlym, to which the Company responded in full. The DOJ's Notice indicates that the DOJ, the California Department of Insurance, and the named Plaintiff States have all declined to intervene in the Relator's lawsuit. On June 2, 2026, the Relator served the Company with an amended complaint. The Company intends to vigorously defend against all of the Relator's claims.